Country: India
Sector: Health Care
Website: http://www.strides.comStrides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
0.31% (5y avg: 1.23%)
2.50 INR
Sept. 9, 2024
6.70%
Year | Total Dividends |
---|---|
2025 | 2.50 INR |
Oct. 25, 2025 (estimated) | 2.5000 |
2024 | 2.50 INR |
Oct. 25, 2024 | 2.5000 |
2023 | 1.50 INR |
Sept. 27, 2023 | 1.5000 |
2021 | 2.50 INR |
Oct. 3, 2021 | 2.5000 |
2020 | 2.00 INR |
Sept. 19, 2020 | 2.0000 |
2019 | 15.00 INR |
Aug. 29, 2019 | 3.0000 |
Aug. 27, 2019 | 12.0000 |
2018 | 2.00 INR |
Oct. 24, 2018 | 2.0000 |
2017 | 4.50 INR |
Oct. 15, 2017 | 4.5000 |
2016 | 4.00 INR |
Aug. 27, 2016 | 4.0000 |
2015 | 108.00 INR |
Aug. 30, 2015 | 3.0000 |
Feb. 1, 2015 | 105.0000 |
2014 | 505.00 INR |
Oct. 30, 2014 | 5.0000 |
Feb. 1, 2014 | 500.0000 |
2013 | 2.00 INR |
June 5, 2013 | 2.0000 |
2012 | 2.00 INR |
May 30, 2012 | 2.0000 |
2011 | 1.50 INR |
June 8, 2011 | 1.5000 |
2010 | 1.50 INR |
June 30, 2010 | 1.5000 |
Yearly aggregated dividends
Strides Pharma Science Limited
Oct 25, 2024 Paid
Dividend
2.5 INR |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion